The American Journal of Managed Care1d
Emerging Therapies Shine Hope on Small Cell Lung Cancer Treatment
Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...
Universiteit Utrecht6d
PhD Defense: Houdini ontmaskerd; de behandeling van TP53-deficiente ALL
PhD Defense of W.P.J. Cox (UMC Utrecht/Kinderen) ...
Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer
Biodexa Strengthens Management TeamAppointment of Dr Gary A. Shangold as Chief Medical OfficerBiodexa Pharmaceuticals PLC ...
Biodexa Pharmaceuticals PLC: Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer
Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (Nasdaq: BDRX), a clinical ...
Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company’s Oncology Pipeline
The Company’s oncology aPKCi inhibitor is a novel, first in class drug candidateWARRINGTON, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: ...
Oryzon Genomics, S.A.: ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome
Exploring the combination with azacitidineStudy led by Medical College of Wisconsin MADRID and CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY) ...
Morningstar14d
Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company’s Oncology Pipeline
The claims also include combination therapies comprising use of the hedgehog pathway inhibitors along with an HDAC inhibitors enhancing anti-cancer efficacy. “Issuance of the new patent for our ...
FierceBiotech27d
Cash-strapped Viracta ends phase 2 study of lead cancer drug as it mulls remaining options
In early November, Viracta said it would be waving goodbye to 42% of its remaining staff in order to keep money flowing to its lead program, a combination of the HDAC inhibitor nanatinostat and ...
Shuttle Pharmaceuticals expands glioblastoma trial
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), a micro-cap pharmaceutical company with a market capitalization of $3.12 million, has amended its agreement with contract research organization ...
Nature28d
Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface
Inhibition by HA-1077 (fasudil ... and drugs such as Scriptaid and SK-7041 block HDAC and suppress pressure-overload hypertrophy. These and other new agents under development pose fertile ground ...